Involvement of Nervous System in Muscle Weakness in COPD Patients (DesCoM-1)
Recruitment status was Recruiting
The purpose of this study is to determine whether nervous system alterations and motor drive failure can contribute to muscle weakness in COPD during voluntary movement. If necessary, we will look after the role of nocturnal hypoxia in these alterations.
Chronic Obstructive Pulmonary Disease
|Study Design:||Observational Model: Case Control
Time Perspective: Cross-Sectional
|Official Title:||Phase 1 Impact of Nocturnal Desaturations on Central Motor Drive in COPD Patients: A New Insight on the Systemic Effects of the Disease.|
|Study Start Date:||July 2012|
|Estimated Study Completion Date:||July 2013|
|Estimated Primary Completion Date:||July 2013 (Final data collection date for primary outcome measure)|
COPD nocturnal desaturator
COPD patients who spend 30% of the nigth with a SaO2 < 90%.
COPD no nocturnal desaturator
COPD patients who spend less than 30% of the night with a SaO2 < 90%
healthy sedentary subjects
COPD is a common disease that induces many systemic repercussions. Among these, peripheral muscle dysfunction is particularly deleterious because it leads to the decreases of the level of activity and the quality of life for patients. Movement involves activation of many structures, from the instructor, i.e. the brain, to the effector, i.e. the muscle. Netherless, the studies which have described peripheral muscle dysfunction have been focused on the muscle, so they have proposed a reducing vision of the phenomenon. Other studies have reported cerebral alterations in COPD, like cognitive disturbance, increase of the neuronal conduction time, and decrease of the white matter density, and were associated with chronic hypoxemia. Such alterations are consistent with the existence of a decrease of the central motor drive during voluntary movement in COPD patients. Therefore the study will aim to determine precisely which mechanisms are involved in peripheral muscle dysfunction in copd.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01679782
|Contact: Francois FA Alexandre, PhD student||0666678916 ext firstname.lastname@example.org|
|Contact: Alain AV Varray, Pr||0411759070 ext email@example.com|
|Clinique du Souffle La Vallonie||Recruiting|
|Lodève, France, 34700|
|Contact: Francois FA Alexandre, PhD student 0666678916 ext 0033 firstname.lastname@example.org|
|Study Director:||Alain AV Varray, Pr||M2H laboratory, Montpellier|